Cancer Patients May Avoid Surgery with Innovative New Therapy

An experimental drug is showing promising results in treating a difficult form of bladder cancer, potentially sparing patients from invasive surgery. The treatment, known as TAR-200, has demonstrated effectiveness against BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), according to recently published clinical trial results.

For patients with this type of cancer, treatment options have traditionally been limited. The standard first-line treatment for early-stage bladder cancers is BCG (Bacillus Calmette-Guérin), an immunotherapy drug. However, when tumors don’t respond to this treatment, patients often face the prospect of complete bladder removal surgery, a procedure that significantly impacts quality of life.

The TAR-200 device offers a novel approach. It’s a small, drug-releasing mechanism that doctors place directly into the bladder through a simple outpatient procedure that doesn’t require general anesthesia. Once inserted, it gradually releases the chemotherapy drug gemcitabine over several weeks, targeting the cancer locally.

“Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer,” said study lead Sia Daneshmand, M.D., director of urologic oncology with Keck Medicine of USC. “The findings of the clinical trial are a breakthrough in how certain types of bladder cancer might be treated, leading to improved outcomes and saved lives.”

Bladder cancer represents a significant health concern, ranking as the fourth most common cancer in men and the eleventh most common in women worldwide. Non-muscle-invasive bladder cancer specifically affects the tissue lining the inner surface of the bladder, and the high-risk variant carries a greater probability of recurrence after treatment.

The clinical trial, sponsored by Janssen Research & Development, LLC, a Johnson & Johnson subsidiary, evaluated multiple treatment groups. In one group, patients received TAR-200 once every three weeks for approximately six months, followed by maintenance treatments every 12 weeks for up to two years.

Results from this group of 85 patients were particularly encouraging, with 82.4% showing no detectable signs of cancer after treatment. More impressively, 52.9% remained cancer-free at the one-year mark, with many continuing to show no cancer recurrence beyond two years without requiring additional treatment.

A second group of patients with a less aggressive form of early-stage bladder cancer also demonstrated positive outcomes. Their disease-free survival rates reached 85.3% at six months and 81.1% at nine months. Perhaps most significantly, 94% of patients in this group were able to preserve their bladders rather than undergoing removal surgery.

“The standard treatment plan for these patients was surgery to remove the bladder and surrounding tissue and organs, which has many health risks and may negatively impact patients’ quality of life,” explained Daneshmand, highlighting the potential quality-of-life improvements this new treatment could offer.

The device’s localized drug delivery approach represents an important innovation in bladder cancer treatment. By delivering gemcitabine directly to the bladder, the medication remains concentrated where it’s needed most, potentially reducing systemic side effects compared to traditional chemotherapy administration methods.

Despite these promising results, the researchers emphasize that the data comes from a mid-stage (Phase 2b) trial. The study lacked a traditional randomized control arm, making definitive comparisons to other treatment approaches difficult. Additionally, the patient population represents a specific subset of bladder cancer cases, and the relatively short follow-up period and modest sample size mean long-term efficacy remains to be fully established.

Larger clinical trials with longer follow-up periods and regulatory reviews will be necessary before TAR-200 could become standard care for patients with this challenging form of bladder cancer. Nevertheless, the initial results provide hope for patients who currently face limited treatment options.

The complete clinical trial results were published earlier this year in the Journal of Clinical Oncology, adding to the growing body of research aimed at improving outcomes for bladder cancer patients.